Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company…


All in on cancer immunotherapy

Founded in 2011, iTeos Therapeutics began its activities at the end of 2012. Active in the field of cancer immunotherapy, the company develops inn…


The Fournier-Majoie Foundation: guiding cancer research to clinical application

At 77 years of age, Bernard Majoie is as active as ever. As founder of the Fournier-Majoie Foundation, he dedicates his time to the battle against…

POPULAR TAGS

iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region

Written by DS on in the category news with the tags , .


iTeos Therapeutics SA, announced that it has been granted EUR 7.5 million in non-dilutive funding to support the clinical development of its lead anti-cancer drug. The funding has been approved on behalf of the Walloon Region by Mr. Jean-Claude Marcourt, Minister for Economy, Industry, Innovation and New technologies.

This additional non-dilutive EUR 7.5 million will be used to partly fund the launch of a clinical trial of iTeos’ proprietary, best-in-class Adenosine Receptor A2A antagonist. The clinical trial is expected to be initiated in Belgium in 2018.

Michel Detheux, Chief Executive Officer of iTeos, commented, "We are grateful to the Minister for Economy, Industry, Innovation and New technologies, Mr Jean-Claude Marcourt, and the Walloon Region for their continued support of iTeos Therapeutics. This additional non-dilutive EUR 7.5 million will partially fund the clinical trial of our proprietary A2A antagonist drug candidate, which is in the exciting field of cancer immunotherapy. During the last three years, iTeos has developed a comprehensive portfolio of immuno-oncology drug candidates and these additional funds will enhance our capability to demonstrate the potential clinical benefits of our products. We look forward to reporting on our progress as we work to develop therapies that we believe could benefit patients with a wide-range of cancers."
 

Read more about: , .

RELATED ARTICLES
Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company…


All in on cancer immunotherapy

Founded in 2011, iTeos Therapeutics began its activities at the end of 2012. Active in the field of cancer immunotherapy, the company develops inn…


The Fournier-Majoie Foundation: guiding cancer research to clinical application

At 77 years of age, Bernard Majoie is as active as ever. As founder of the Fournier-Majoie Foundation, he dedicates his time to the battle against…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Itera Life Science Biowin V-Bio Ventures Turnstone KU Leuven UGent Janssen GSK Flanders.bio XpandInnovation

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.